Prevalence of diabetes mellitus and its associated comorbidities: a population based study
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20241211Keywords:
Type 2 diabetes mellitus, Multimorbidity, HyperlipidaemiaAbstract
The purpose of this study was to quantify the prevalence and co-prevalence of common comorbidities of type 2 diabetes mellitus (T2DM). Literature search was conducted in PubMed for relevant articles published during the period from 2013 to 2023. Studies describing the prevalence rate of T2DM and its associated co-morbidities in INDIA in the past 10 years and the pharmaceutical antidiabetic treatment were identified. Out of 100 articles 10 studies conducted in India fulfilled the inclusion criteria regarding the prevalence rate of T2DM along with its associated co-morbidities. Studies revealed that comorbidity burden tended to increase in older age groups and was higher in men than women. Few studies demonstrated for the combination of hypertension (HTN) and hyperlipidaemia (67.5%), followed by overweight/obesity and HTN (66.0%), overweight/obesity and hyperlipidaemia (62.5%), HTN and chronic kidney disease (CKD) (22.4%), hyperlipidaemia and CKD (21.1%), HTN and cardiovascular disease (CVD) (20.2%), hyperlipidaemia and CVD (20.1%), overweight/obesity and CKD (19.1%) and overweight/obesity and CVD (17.0%). The most common conditions in patients with T2DM included HTN in 82.1%; overweight/obesity in 78.2%; hyperlipidaemia in 77.2%; CKD in 24.1%; and CVD in 21.6%. It was concluded from the study that the vast majority of patients with T2DM have multiple comorbidities. To ensure a comprehensive approach to patient management, the presence of multimorbidity should be considered in the context of clinical decision making.
Metrics
References
Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation. 2016;133(2):187-225.
WHO. WHO Global report on diabetes, 2016. Available at: https://www.who.int/health-topics/diabetes?gad_source=1&gclid=Cj0KCQjwlZixBhCoARIsAIC745AeJYIA5U0a4naz5e0kBSitW5mqEDnhVg. Accessed on 15 February 2024.
Chamberlain JJ, Rhinehart AS, Shaefer CF, Neuman A. Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2016;164(8):542-52.
Salvo MC, Brooks AD, Thacker SM. Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin. Patient Prefer Adherence. 2014;8:493-502.
Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243-52.
Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29(3):725-31.
Maniarasu K, Muthunarayanan L. Prevalence of certain chronic complications of diabetes among type 2 diabetic patients in rural population of Kancheepuram District, Tamil Nadu-a cross sectional study. Int J Med Public Health. 2017;7(1):41-6.
Ray J, Sahoo CK, Mohanty R, Sahoo R, Dalai, R. A review on diabetic peripheral neuropathy. J Drug Deliv Therap. 2015;11(2-S):121-5.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
Babu GR, Murthy GVS, Ana Y, Patel P, Deepa R, Neelon SEB, et al. Association of obesity with hypertension and type 2 diabetes mellitus in India: A meta-analysis of observational studies. World J Diabetes. 2018;9(1):40-52.
Wani FA, Koul RK, Raina AA, Nazir A, Maqbool M, Bhat MH, et al. Prevalence of microvascular complications in newly diagnosed type-2 diabetes mellitus. Int J Sci Stud. 2016;3(10):102-5.
Borgharkar SS, Das SS. Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study. BMJ Open Diabetes Res Care. 2019;7(1):e000654.
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(10):938-53.
Mythili A, Kumar KD, Subrahmanyam KA, Venkateswarlu K, Butchi RG. A Comparative study of examination scores and quantitative sensory testing in diagnosis of diabetic polyneuropathy. Int J Diabetes Dev Ctries. 2010;30(1):43-8.
Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31(12):2383-90.
Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care. 2008;31(3):420-6.
Kammer JR, Hosler AS, Leckman-Westin E, DiRienzo G, Osborn CY. The association between antidepressant use and glycemic control in the Southern Community Cohort Study (SCCS). J Diabetes Complications. 2016;30(2):242-7.
McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006;5(1):157-68.
Deuschle M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr Opin Psychiatry. 2013;26(1):60-5.
Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care. 2008;31(3):420-6.
Kim GM, Woo JM, Jung SY, Shin S, Song HJ, Park J, Ahn J. Positive association between serious psychiatric outcomes and complications of diabetes mellitus in patients with depressive disorders. Int J Psychiatry Med. 2015;50(2):131-46.
